Advertisement

Topical therapy I: corticosteroids and vitamin D analogs

  • Paru R. Chaudhari
  • Dana K. Stern
  • Mark G. Lebwohl
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

Topical therapy is the first-line of treatment for mild to moderate psoriasis (see Tab. 1). The following two chapters will describe the available topical therapies for psoriasis, providing insight into the progress that has been made for treatment of the disease. This chapter will focus on the most widely used topical regimens, topical corticosteroids and vitamin D analogs, while the subsequent chapter will examine additional topical therapies used to treat psoriasis.

Keywords

Topical Corticosteroid Topical Therapy Mometasone Furoate Clobetasol Propionate Fluocinolone Acetonide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sulzberger MB, Witten VH (1952) The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 19: 101–102PubMedGoogle Scholar
  2. 2.
    Hughes J, Rustin M (1997) Corticosteroids. Clin Dermatol 15: 715–721PubMedCrossRefGoogle Scholar
  3. 3.
    Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr, (1995) Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270: 283–286PubMedCrossRefGoogle Scholar
  4. 4.
    Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270: 286–290PubMedCrossRefGoogle Scholar
  5. 5.
    Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB (1991) Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol 146: 3523–3527PubMedGoogle Scholar
  6. 6.
    Del Rosso J, Friedlander SF (2005) Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol 53: S50–58PubMedCrossRefGoogle Scholar
  7. 7.
    Lebwohl M, Ali S (2001) Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 45: 487–498; quiz 499–502PubMedCrossRefGoogle Scholar
  8. 8.
    Nathan AW, Rose GL (1979) Fatal iatrogenic Cushing’s syndrome. Lancet 1: 207PubMedCrossRefGoogle Scholar
  9. 9.
    Reichert-Penetrat S, Trechot P, Barbaud A, Gillet P, Schmutz JL (2001) Bilateral femoral avascular necrosis in a man with psoriasis: responsibility of topical corticosteroids and role of cyclosporine. Dermatology 203: 356–357PubMedCrossRefGoogle Scholar
  10. 10.
    Kane D, Barnes L, Fitzgerald O (2003) Topical corticosteroid treatment: systemic side-effects. Br J Dermatol 149: 417PubMedCrossRefGoogle Scholar
  11. 11.
    Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI (1998) Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol 38: 318–321PubMedCrossRefGoogle Scholar
  12. 12.
    Ermis B, Ors R, Tastekin A, Ozkan B (2003) Cushing’s syndrome secondary to topical corticosteroids abuse. Clin Endocrinol (Oxf) 58: 795–796CrossRefGoogle Scholar
  13. 13.
    Nielsen NV, Sorensen PN (1978) Glaucoma induced by application of corticosteroids to the periorbital region. Arch Dermatol 114: 953–954PubMedCrossRefGoogle Scholar
  14. 14.
    du Vivier A, Stoughton RB (1975) Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 111: 581–583PubMedCrossRefGoogle Scholar
  15. 15.
    Miller JJ, Roling D, Margolis D, Guzzo C (1999) Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol 41: 546–549PubMedGoogle Scholar
  16. 16.
    Feldman SR (2006) Tachyphylaxis to topical corticosteroids: the more you use them, the less they work? Clin Dermatol 24: 229–230; discussion 230PubMedCrossRefGoogle Scholar
  17. 17.
    Dunna SF, Finlay AY (1989) Psoriasis: improvement during and worsening after pregnancy. Br J Dermatol 120: 584PubMedCrossRefGoogle Scholar
  18. 18.
    Katz VL, Thorp JM Jr, Bowes WA Jr, (1990) Severe symmetric intrauterine growth retardation associated with the topical use of triamcinolone. Am J Obstet Gynecol 162: 396–397PubMedGoogle Scholar
  19. 19.
    Turpeinen M, Salo OP, Leisti S (1986) Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 115: 475–484PubMedCrossRefGoogle Scholar
  20. 20.
    Lucky AW, Grote GD, Williams JL, Tuley MR, Czernielewski JM, Dolak TM, Herndon JH, Baker MD (1997) Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis 59: 151–153PubMedGoogle Scholar
  21. 21.
    Vermeer BJ, Heremans GF (1974) A case of growth retardation and cushing’s syndrome due to excessive application of betamethasone-17-valerate ointment. Dermatologica 149: 299–304PubMedGoogle Scholar
  22. 22.
    Hengge UR, Ruzicka T, Schwartz RA, Cork MJ (2006) Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 54: 1–15; quiz 16–18PubMedCrossRefGoogle Scholar
  23. 23.
    Cornell RC, Stoughton RB (1985) Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 121: 63–67PubMedCrossRefGoogle Scholar
  24. 24.
    Lebwohl M (2005) A clinician’s paradigm in the treatment of psoriasis. J Am Acad Dermatol 53: S59–69PubMedCrossRefGoogle Scholar
  25. 25.
    Thomas KS, Armstrong S, Avery A, Po AL, O’Neill C, Young S, Williams HC (2002) Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ 324: 768PubMedCrossRefGoogle Scholar
  26. 26.
    Lebwohl MG, Tan MH, Meador SL, Singer G (2001) Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 44: 77–82PubMedCrossRefGoogle Scholar
  27. 27.
    Pardasani AG, Feldman SR, Clark AR (2000) Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician 61: 725–733, 736PubMedGoogle Scholar
  28. 28.
    Lebwohl M, Peets E, Chen V (1993) Limited application of mometasone furoate on the face and intertriginous areas: analysis of safety and efficacy. Int J Dermatol 32: 830–831PubMedCrossRefGoogle Scholar
  29. 29.
    Korting HC, Kerscher MJ, Schafer-Korting M (1992) Topical glucocorticoids with improved benefit/risk ratio: do they exist? J Am Acad Dermatol 27: 87–92PubMedCrossRefGoogle Scholar
  30. 30.
    Schafer-Korting M, Schmid MH, Korting HC (1996) Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept. Drug Saf 14: 375–385PubMedCrossRefGoogle Scholar
  31. 31.
    Huang X, Tanojo H, Lenn J, Deng CH, Krochmal L (2005) A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol 53: S26–38PubMedCrossRefGoogle Scholar
  32. 32.
    Stein L (2005) Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol 53: S39–49PubMedCrossRefGoogle Scholar
  33. 33.
    Franz TJ, Parsell DA, Myers JA, Hannigan JF (2000) Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. Int J Dermatol 39: 535–538PubMedCrossRefGoogle Scholar
  34. 34.
    Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS (1999) Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 38: 628–632PubMedCrossRefGoogle Scholar
  35. 35.
    Lebwohl M, Menter A, Koo J, Feldman SR (2004) Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 50: 416–430PubMedCrossRefGoogle Scholar
  36. 36.
    Meola T Jr, Soter NA, Lim HW (1991) Are topical corticosteroids useful adjunctive therapy for the treatment of psoriasis with ultraviolet radiation? A review of the literature. Arch Dermatol 127: 1708–1713PubMedCrossRefGoogle Scholar
  37. 37.
    Schmoll M, Henseler T, Christophers E (1978) Evaluation of PUVA, topical corticosteroids and the combination of both in the treatment of psoriasis. Br J Dermatol 99: 693–702PubMedCrossRefGoogle Scholar
  38. 38.
    Morison WL, Parrish JA, Fitzpatrick TB (1978) Controlled study of PUVA and adjunctive topical therapy in the management of psoriasis. Br J Dermatol 98: 125–132PubMedCrossRefGoogle Scholar
  39. 39.
    Morimoto S, Kumahara Y (1985) A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. Med J Osaka Univ 35: 51–54PubMedGoogle Scholar
  40. 40.
    Smith EL, Walworth NC, Holick MF (1986) Effect of 1 alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 86: 709–714PubMedCrossRefGoogle Scholar
  41. 41.
    Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T (1983) Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3. Endocrinology 113: 1950–1957PubMedGoogle Scholar
  42. 42.
    Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240: 889–895PubMedCrossRefGoogle Scholar
  43. 43.
    Binderup L, Bramm E (1988) Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 37: 889–895PubMedCrossRefGoogle Scholar
  44. 44.
    Lee E, Jeon SH, Yi JY, Jin YJ, Son YS (2001) Calcipotriol inhibits autocrine phosphorylation of EGF receptor in a calcium-dependent manner, a possible mechanism for its inhibition of cell proliferation and stimulation of cell differentiation. Biochem Biophys Res Commun 284: 419–425PubMedCrossRefGoogle Scholar
  45. 45.
    Kragballe K, Wildfang IL (1990) Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res 282: 164–167PubMedCrossRefGoogle Scholar
  46. 46.
    Nagpal S, Lu J, Boehm MF (2001) Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem 8: 1661–1679PubMedGoogle Scholar
  47. 47.
    Kragballe K, Gjertsen BT, De Hoop D, Karlsmark T, van de Kerkhof PC, Larko O, Nieboer C, Roed-Petersen J, Strand A, Tikjob G (1991) Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 337: 193–196PubMedCrossRefGoogle Scholar
  48. 48.
    Cunliffe WJ, Berth-Jones J, Claudy A, Fairiss G, Goldin D, Gratton D, Henderson CA, Holden CA, Maddin WS, Ortonne JP et al. (1992) Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 26: 736–743PubMedGoogle Scholar
  49. 49.
    Perez A, Chen TC, Turner A, Raab R, Bhawan J, Poche P, Holick MF (1996) Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis. Br J Dermatol 134: 238–246PubMedCrossRefGoogle Scholar
  50. 50.
    van de Kerkhof PC, Berth-Jones J, Griffiths CE, Harrison PV, Honigsmann H, Marks R, Roelandts R, Schopf E, Trompke C (2002) Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol 146: 414–422PubMedCrossRefGoogle Scholar
  51. 51.
    Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P (1993) Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double-blind, placebo-controlled study. Acta Derm Venereol 73: 300–304PubMedGoogle Scholar
  52. 52.
    Berth-Jones J, Bourke JF, Iqbal SJ, Hutchinson PE (1993) Urine calcium excretion during treatment of psoriasis with topical calcipotriol. Br J Dermatol 129: 411–414PubMedCrossRefGoogle Scholar
  53. 53.
    Georgiou S, Tsambaos D (1999) Hypercalcaemia and hypercalciuria after topical treatment of psoriasis with excessive amounts of calcipotriol. Acta Derm Venereol 79: 86PubMedCrossRefGoogle Scholar
  54. 54.
    Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE (1993) High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br J Dermatol 129: 74–76PubMedCrossRefGoogle Scholar
  55. 55.
    Russell S, Young MJ (1994) Hypercalcaemia during treatment of psoriasis with calcipotriol. Br J Dermatol 130: 795–796PubMedCrossRefGoogle Scholar
  56. 56.
    Hardman KA, Heath DA, Nelson HM (1993) Hypercalcaemia associated with calcipotriol (Dovonex) treatment. BMJ 306: 896PubMedGoogle Scholar
  57. 57.
    Kawaguchi M, Mitsuhashi Y, Kondo S (2003) Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis. J Dermatol 30: 801–804PubMedGoogle Scholar
  58. 58.
    Tauscher AE, Fleischer AB Jr, Phelps KC, Feldman SR (2002) Psoriasis and pregnancy. J Cutan Med Surg 6: 561–570PubMedCrossRefGoogle Scholar
  59. 59.
    Darley CR, Cunliffe WJ, Green CM, Hutchinson PE, Klaber MR, Downes N (1996) Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol 135: 390–393PubMedCrossRefGoogle Scholar
  60. 60.
    Oranje AP, Marcoux D, Svensson A, Prendiville J, Krafchik B, Toole J, Rosenthal D, de Waardvan der Spek FB, Molin L, Axelsen M (1997) Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol 36: 203–208PubMedCrossRefGoogle Scholar
  61. 61.
    Kragballe K, Beck HI, Sogaard H (1988) Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind study. Br J Dermatol 119: 223–230PubMedCrossRefGoogle Scholar
  62. 62.
    Kragballe K (1989) Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903). Arch Dermatol 125: 1647–1652PubMedCrossRefGoogle Scholar
  63. 63.
    Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, Chevrant-Breton J, Beylot C, Bazex JA, Jurgensen HJ (1992) Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 27: 983–988PubMedCrossRefGoogle Scholar
  64. 64.
    Berardesca E, Vignoli GP, Farinelli N, Vignini M, Distante F, Rabbiosi G (1994) Non-invasive evaluation of topical calcipotriol versus clobetasol in the treatment of psoriasis. Acta Derm Venereol 74: 302–304PubMedGoogle Scholar
  65. 65.
    Bruce S, Epinette WW, Funicella T, Ison A, Jones EL, Loss R Jr, McPhee ME, Whitmore C (1994) Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 31: 755–759PubMedGoogle Scholar
  66. 66.
    Camarasa JM, Ortonne JP, Dubertret L (2003) Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat 14: 8–13PubMedCrossRefGoogle Scholar
  67. 67.
    Wall AR, Poyner TF, Menday AP (1998) A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. Br J Dermatol 139: 1005–1011PubMedCrossRefGoogle Scholar
  68. 68.
    Thaci D, Daiber W, Boehncke WH, Kaufmann R (2001) Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3’396 patients. Dermatology 203: 153–156PubMedCrossRefGoogle Scholar
  69. 69.
    Ortonne JP, Humbert P, Nicolas JF, Tsankov N, Tonev SD, Janin A, Czernielewski J, Lahfa M, Dubertret L (2003) Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(−1) ointment and calcipotriol 50 microg g(−1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol 148: 326–333PubMedCrossRefGoogle Scholar
  70. 70.
    Takahashi H, Ibe M, Kinouchi M, Ishida-Yamamoto A, Hashimoto Y, Iizuka H (2003) Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 31: 21–28PubMedCrossRefGoogle Scholar
  71. 71.
    Van de Kerkhof PC, Werfel T, Haustein UF, Luger T, Czarnetzki BM, Niemann R, Planitz-Stenzel V (1996) Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety. Br J Dermatol 135: 758–765PubMedCrossRefGoogle Scholar
  72. 72.
    Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB (1997) Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol 137: 581–586PubMedCrossRefGoogle Scholar
  73. 73.
    Barker JN, Ashton RE, Marks R, Harris RI, Berth-Jones J (1999) Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 141: 274–278PubMedCrossRefGoogle Scholar
  74. 74.
    Durakovic C, Ray S, Holick MF (2004) Topical paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: a pilot study. Br J Dermatol 151: 190–195PubMedCrossRefGoogle Scholar
  75. 75.
    Lebwohl M, Siskin SB, Epinette W, Breneman D, Funicella T, Kalb R, Moore J (1996) A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 35: 268–269PubMedCrossRefGoogle Scholar
  76. 76.
    Lebwohl M, Yoles A, Lombardi K, Lou W (1998) Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 39: 447–450PubMedCrossRefGoogle Scholar
  77. 77.
    Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C et al. (2002) A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 82: 131–135PubMedCrossRefGoogle Scholar
  78. 78.
    Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, van de Kerkhof PC, Hanssen LI et al. (2003) Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 48: 48–54PubMedCrossRefGoogle Scholar
  79. 79.
    Guenther L, Van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, Garcia-Diez A, Springborg J (2002) Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 147: 316–323PubMedCrossRefGoogle Scholar
  80. 80.
    Ortonne JP, Kaufmann R, Lecha M, Goodfield M (2004) Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 209: 308–313PubMedCrossRefGoogle Scholar
  81. 81.
    Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM (2004) Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 150: 1167–1173PubMedCrossRefGoogle Scholar
  82. 82.
    Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, Fleming C, Heikkila H, Jolliffe D, Peyri J et al. (2006) A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 154: 1155–1160PubMedCrossRefGoogle Scholar
  83. 83.
    Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, Fleming C, Heikkila H, Williams Z, Peyri Rey J et al. (2006) Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 213: 319–326PubMedCrossRefGoogle Scholar
  84. 84.
    White S, Vender R, Thaci D, Haverkamp C, Naeyaert JM, Foster R, Martinez Escribano JA, Cambazard F, Bibby A (2006) Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. Am J Clin Dermatol 7: 177–184PubMedCrossRefGoogle Scholar
  85. 85.
    Kragballe K, van de Kerkhof PC (2006) Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol 20: 39–44PubMedCrossRefGoogle Scholar
  86. 86.
    Blum RR, Stern D, Lebwohl M, Bandow G, Koo J, Cheplo K (2004) A multi-center study of calcipotriene ointment, 0.005% and clobetasol propionate foam, 0.05% in the sequential treatment of localized plaque-type psoriasis. Summer Meeting of the American Academy of Dermatology, New York, NYGoogle Scholar
  87. 87.
    Koo J, Blum RR, Lebwohl M (2006) A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short-and long-term outcomes. J Am Acad Dermatol 55: 637–641PubMedCrossRefGoogle Scholar
  88. 88.
    Bowman PH, Maloney JE, Koo JY (2002) Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 46: 907–913PubMedCrossRefGoogle Scholar
  89. 89.
    Patel B, Siskin S, Krazmien R, Lebwohl M (1998) Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 38: 1010–1011PubMedCrossRefGoogle Scholar
  90. 90.
    Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE (2000) Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability. Arch Dermatol 136: 1536–1543PubMedCrossRefGoogle Scholar
  91. 91.
    Hecker D, Lebwohl M (1997) Topical calcipotriene in combination with UVB phototherapy for psoriasis. Int J Dermatol 36: 302–303PubMedCrossRefGoogle Scholar
  92. 92.
    Molin L (1999) Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group. Dermatology 198: 375–381PubMedCrossRefGoogle Scholar
  93. 93.
    Kragballe K (1990) Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris. Dermatologica 181: 211–214PubMedCrossRefGoogle Scholar
  94. 94.
    Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M (2000) Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology 200: 17–24PubMedCrossRefGoogle Scholar
  95. 95.
    Brands S, Brakman M, Bos JD, de Rie MA (1999) No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis. J Am Acad Dermatol 41: 991–995PubMedCrossRefGoogle Scholar
  96. 96.
    Frappaz A TJ (1993) Calcipotriol in combination with PUVA: a randomized double placebo study in severe psoriasis. Eur J Dermatol 3: 351–354Google Scholar
  97. 97.
    Lebwohl M, Hecker D, Martinez J, Sapadin A, Patel B (1997) Interactions between calcipotriene and ultraviolet light. J Am Acad Dermatol 37: 93–95PubMedCrossRefGoogle Scholar
  98. 98.
    van de Kerkhof PC, Cambazard F, Hutchinson PE, Haneke E, Wong E, Souteyrand P, Damstra RJ, Combemale P, Neumann MH, Chalmers RJ et al. (1998) The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 138: 84–89PubMedCrossRefGoogle Scholar
  99. 99.
    de Jong EM, Mork NJ, Seijger MM, De La Brassine M, Lauharanta J, Jansen CT, Guilhou JJ, Guillot B, Ostrojic A, Souteyrand P et al. (2003) The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol 148: 318–325PubMedCrossRefGoogle Scholar
  100. 100.
    Grossman RM, Thivolet J, Claudy A, Souteyrand P, Guilhou JJ, Thomas P, Amblard P, Belaich S, de Belilovsky C, de la Brassinne M et al. (1994) A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 31: 68–74PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2008

Authors and Affiliations

  • Paru R. Chaudhari
    • 1
  • Dana K. Stern
    • 1
  • Mark G. Lebwohl
    • 1
  1. 1.Mount Sinai School of Medicine Department of DermatologyNew YorkUSA

Personalised recommendations